OHR Pharmaceutical Inc (NASDAQ:OHRP)’s share price hit a new 52-week high and low on Wednesday following a better than expected earnings announcement. The stock traded as low as $0.19 and last traded at $0.19, with a volume of 700 shares changing hands. The stock had previously closed at $0.19.
The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.02.
Separately, ValuEngine raised shares of OHR Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The stock has a market capitalization of $11.40 million, a PE ratio of -0.36 and a beta of 0.14.
OHR Pharmaceutical Company Profile
OHR Pharmaceutical, Inc, a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.